

**Amendments to the Drawings**

*Please replace FIG. 5 on one original drawing sheet with replacement FIG. 5 on one replacement drawing sheet.*


One replacement drawing sheet, upon which is shown corrected FIG. 5, is filed online herewith. The changes made to FIG. 5 are fully described in the remarks (below) and would not be easily shown in an annotated drawing. Therefore, an optional annotated drawing is not provided (MPEP 608.02(p)).

### Remarks

The present application is a U.S. national stage of PCT Application No. PCT/CA2003/001389 ("PCT Application"). Upon entry into the U.S. national stage, Applicants filed a first Preliminary Amendment that, in part, replaced all of the drawings in the PCT Application. The replacement drawings were filed in the first Preliminary Amendment to provide "clear copies of the sheets filed at the International Stage."

Applicants have recently recognized that FIG. 5 submitted with the first Preliminary Amendment was not an accurate replacement for original FIG. 5 as filed with the PCT Application. Thus, this Second Preliminary Amendment provides a replacement FIG. 5 that, except as discussed below, mirrors original FIG. 5 and is a clearer copy of that original figure.

Original FIG. 5 is reproduced below:



This original figure is a bar graph showing, among other data, inhibition of CD45 phosphatase activity by gangliosides GD2 and GD3. As described in the specification (*e.g.*, at page 30, lines 27-30), FIG. 5 should show that "GD2 can drastically inhibit CD45 phosphatase activity (85% inhibition), while . . . GD3 . . . had little influence on the enzymatic activity of CD45." Original FIG. 5 clearly misrepresented these results because GD2 was shown to have


little effect on CD45 activity, while GD3 was shown to inhibit 85% of CD45 activity. Based on the results described in the specification, it is clear that the labels for GD2 and GD3 in original FIG. 5 were inadvertently swapped. Accordingly, replacement FIG. 5 filed herewith corrects this obvious error.

Examination of the pending claims is respectfully requested.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 595-5301

By:   
Debra A. Gordon, Ph.D.  
Registration No. 54,128